Phytopharm plc (LSE: PYM; NASDAQBB: PHYOF; PHYOY) (“Phytopharm”) announces today that it has successfully completed the first stage of the Joint Development Agreement for Hoodia gordonii extract with Unilever and will now progress to the second stage which includes clinical safety studies.
